Jaguar LAA acquires Johnson & Johnson Laminar assets for atrial fibrillation programme
Jaguar LAA has acquired assets from Johnson & Johnson related to the Laminar left atrial appendage closure programme, creating a newly independent medical-device company focused on advancing the technology.
The transaction transfers the Laminar programme and associated assets to Jaguar LAA, which has also brought key programme personnel into the new organisation to continue development of the left atrial appendage closure platform.
Jaguar LAA plans to advance the programme through additional development and regulatory activity, positioning the company to continue work on a potential device-based approach to reducing stroke risk in patients with atrial fibrillation.
Field | Content |
Alert Type | Deal |
Companies | Jaguar LAA; Johnson & Johnson |
Deal Type | Asset acquisition |
Asset or Company | Laminar left atrial appendage closure programme |
Therapy Area(s) | Cardiology; atrial fibrillation; structural heart |
Technology or Modality | Left atrial appendage closure medical device |
Deal Value | Financial terms were not disclosed |
Geography | United States |
What Happened | Jaguar LAA acquired Johnson & Johnson assets related to the Laminar left atrial appendage closure programme and brought key programme personnel into the newly formed independent company. |
Why It Matters | The transaction preserves development of the Laminar technology outside Johnson & Johnson and creates a dedicated organisation focused on advancing the programme toward further regulatory and commercial milestones. |
Supporting Context | Left atrial appendage closure devices are designed to reduce stroke risk in selected patients with atrial fibrillation by isolating the appendage, where blood clots can form. |
Strategic Rationale | Jaguar LAA gains control of an established medtech programme, intellectual property and experienced personnel while creating a focused development organisation around the Laminar platform. |
Potential Impact | Successful development and regulatory approval could add another device-based option for stroke prevention in patients with atrial fibrillation. |
Key Takeaway | Jaguar LAA has acquired the Laminar left atrial appendage closure assets from Johnson & Johnson and will continue development of the programme independently. |
What to Watch | Future clinical development, regulatory submissions and financing milestones for the Laminar programme. |
Primary Source | PR Newswire |
Relevant Date | 11 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Kommentare